In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

Elevations in cardiac troponin (cTn) after long bouts of aerobic exercise are not associated with subclinical coronary artery ...

Only a minority consistently meet timely targets set out by the AHA and ACC. This is a “call to action,” Harold Dauerman says ...

Outcomes in the observational study were better among patients treated by surgeons who regularly do ablations.

Photo Credit: Adapted from Reardon MJ. A closer look at the ACURATE IDE study. Presented at: TCT 2024. Washington, DC. Underexpansion of the Acurate neo and neo2 transcatheter heart valves (Boston ...

Sources. Araújo CGS, de Souza e Silva CG, Myers J, et al. Sitting–rising test scores predict natural and cardiovascular causes of deaths in middle-aged and older men and women. European Journal of ...